Vertex CEO Jeffrey Leiden has offered an olive branch to negotiators in the UK that could see the cystic fibrosis drug Orkambi finally supplied to patients in England.

Vertex’s Orkambi (lumacaftor+ivacaftor) cystic fibrosis drug is to be reimbursed in Australia’s publicly funded health system after it was cleared by a cost-effectiveness committee. The ...